BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33037739)

  • 1. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
    Zhang D; Meng F
    ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
    Spinello A; Borišek J; Malcovati L; Magistrato A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
    Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
    Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
    Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
    Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
    Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
    Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
    Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
    Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
    Webb TR; Joyner AS; Potter PM
    Drug Discov Today; 2013 Jan; 18(1-2):43-9. PubMed ID: 22885522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
    Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
    Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.
    Maji D; Grossfield A; Kielkopf CL
    Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194440. PubMed ID: 31707043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
    Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
    Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
    Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
    Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
    Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pre-mRNA splicing and transcription factor Tat-SF1 is a functional partner of the spliceosome SF3b1 subunit via a U2AF homology motif interface.
    Loerch S; Leach JR; Horner SW; Maji D; Jenkins JL; Pulvino MJ; Kielkopf CL
    J Biol Chem; 2019 Feb; 294(8):2892-2902. PubMed ID: 30567737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.